Trial · NCT00504504
Rituximab and ABVD for Hodgkin's Patients
NCT00504504, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2013-07-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rituximab and ABVD for Hodgkin's Patients. Trials, record NCT00504504. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00504504
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rituximab and ABVD for Hodgkin's Patients
- NCT number
- NCT00504504
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 85 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Lymphoma
- Interventions
- Rituximab, Adriamycin, Bleomycin, Vinblastine, Dacarbazine (DTIC)
- First posted
- 2007-07-20
- Last updated
- 2013-07-09
- Results first posted
- 2013-07-09
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 5-year Failure-free Survival Rate for Participants With Hodgkin's Disease Given Rituximab With ABVD | Baseline to 5 Years or until disease progression | Five year Event Free Survival (EFS) is proportion of surviving participants who remain event free out of total participants at 5 years after receiving Rituximab + ABVD (RABVD). Event-free Survival (EFS) analyzed every 6 months. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 5-year Failure-free Survival Rate for Participants With Hodgkin's Disease Given Rituximab With ABVD | Baseline to 5 Years or until disease progression | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 5-year Failure-free Survival Rate for Participants With Hodgkin's Disease Given Rituximab With ABVD | Rituximab + ABVD Chemotherapy | 83 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Rituximab + ABVD Chemotherapy | 82 | |
| Overall Study | COMPLETED | Rituximab + ABVD Chemotherapy | 82 | |
| Overall Study | NOT COMPLETED | Rituximab + ABVD Chemotherapy | 0 |
Source ClinicalTrials.gov
Adverse events19
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Rituximab + ABVD Chemotherapy | 32 | 82 | |
| other | Pain | General disorders | Rituximab + ABVD Chemotherapy | 28 | 82 | |
| other | Alopecia | General disorders | Rituximab + ABVD Chemotherapy | 35 | 82 | |
| other | Nausea | Gastrointestinal disorders | Rituximab + ABVD Chemotherapy | 45 | 82 | |
| other | Vomiting | Gastrointestinal disorders | Rituximab + ABVD Chemotherapy | 28 | 82 | |
| other | Diarrhea | Gastrointestinal disorders | Rituximab + ABVD Chemotherapy | 16 | 82 | |
| other | Constipation | Gastrointestinal disorders | Rituximab + ABVD Chemotherapy | 19 | 82 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Rituximab + ABVD Chemotherapy | 16 | 82 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Rituximab + ABVD Chemotherapy | 15 | 82 | |
| other | Neuropathy | Nervous system disorders | Rituximab + ABVD Chemotherapy | 25 | 82 |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Rituximab + ABVD Chemotherapy | ||
| Total, other adverse events | Rituximab + ABVD Chemotherapy | 82 | 82 |
| Total, serious adverse events | Rituximab + ABVD Chemotherapy | 40 | 82 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22371887 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00504504
GET https://conductscience.org/api/trials/v1/NCT00504504/registered